Norditropin (somatropin (rDNA origin) for injection)

Company
Novo Nordisk

Approval Status
Approved February 1997

Treatment for
Growth failure in children

Areas
Diabetes / Endocrinology , Pediatrics

Norditropin is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of endogenous (pituitary gland produced) growth hormone.

Human growth hormone is responsible for stimulating normal skeletal, connective tissue, muscle and organ growth in children and adolescents. It is also active in normal protein, carbohydrate and fat metabolism. If the amount of growth hormone production by the body is insufficient, short stature, reduced muscle and soft tissue mass and altered nutrient metabolism result. Such problems significantly impact an individual’s physical function throughout life, if not treated appropriately.

Norditropin (somatropin (rDNA origin) for injection) Drug Information

The Norditropin (somatropin (rDNA origin) for injection) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top